摘要
背景:阿尔茨海默症(AD)是痴呆的最常见形式。任何认知缺失的症状经过20年都可能发展成为AD。因此,早期诊断和保护系统的发展都非常重要。AD的机制现仍存在争论。然而,AD患者脑脊液和血浆中被检测到高水平的糖化白蛋白。因此,糖化白蛋白可能成为AD发展中的生物标记物。 途径:电化学生物传感器精确检测糖化白蛋白是基于由二乙烯三胺五乙酸(DTPA)的钴(II) 螯合物构成的金电极表面。组氨酸标记的晚期糖基化终末产物(RAGE)受体的区域被当作糖化白蛋白的活性分析元素。糖化白蛋白与组氨酸6-晚期糖基化终末产物的连接由奥斯特扬方波伏安法检测。 结果:通过组氨酸6-晚期糖基化终末产物VC1自然领域修饰的电极使糖化白蛋白钴(II) 的氧化还原反应减少。人体白蛋白,Aβ 1-40 和 S100B 蛋白对生物传感器回应糖化白蛋白的影响可忽略不计。在不同的缓冲液条件下,检测限分别为2.3pM(缓冲液),1.1pM(含白蛋白缓冲液),2.9pM(含S100B缓冲液),3.1pM(含Aβ1-40 缓冲液)。 结论:现在的电化学生物传感器已经成功应用于糖化白蛋白的检测。考虑到分析参数(如在pM级别的好的选择性和灵敏度),生物传感器可能成为一种药物样品分析的工具。
关键词: 阿尔茨海默症,喷替酸-钴螯合物,糖化白蛋白,组氨酸标记的晚期糖基化终末产物区域,电化学生物传感器,氧化还原活性单层,潜在AD生物标记物
Current Alzheimer Research
Title:Electrochemical Biosensor for the Detection of Glycated Albumin
Volume: 14 Issue: 3
关键词: 阿尔茨海默症,喷替酸-钴螯合物,糖化白蛋白,组氨酸标记的晚期糖基化终末产物区域,电化学生物传感器,氧化还原活性单层,潜在AD生物标记物
摘要: Background: Alzheimer’s disease (AD) is the most common form of dementia. The process of AD can begin 20 years before any symptom of cognitive loss. Thus, the development of systems for early diagnosis and prevention is very important. The mechanism of AD is still under debate. Nevertheless, higher levels of glycated albumin in cerebrospinal fluid and plasma are observed in AD patients. Therefore, glycated albumin could be a biomarker of AD development.
Methods: Electrochemical biosensor for direct determination of glycated albumin was based on thiol derivative of pentetic acid (DTPA) complex with Cu(II) created on gold electrode surface. His-tagged domains of Receptors for Advanced Glycation End Products (RAGE) were applied as analytical active element for glycated albumin recognition. The binding of glycated albumin by His6- RAGE domains was monitored using Osteryoung square - wave voltammetry. Results: Electrodes modified with His6 - RAGE VC1 natural domain generated decrease of Cu(II) redox currents in the presence of glycated albumin. Human albumin, Aβ 1-40 and S100B protein caused negligible influence on biosensors responses towards glycated albumin. The detection limits were: 2.3 pM, 1.1 pM, 2.9 pM and 3.1 pM in the presence of: buffer, buffer + albumin, buffer + S100B, buffer + Aβ1-40 , respectively. Conclusion: The presented electrochemical biosensor was successfully applied for the determination of glycated albumin. Considering analytical parameters such as good selectivity and sensitivity in pM range, biosensor could be recommended as an analytical tool for medical samples analysis.Export Options
About this article
Cite this article as:
Electrochemical Biosensor for the Detection of Glycated Albumin, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161108110542
DOI https://dx.doi.org/10.2174/1567205013666161108110542 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) O-GlcNAc Modification and the Tauopathies: Insights from Chemical Biology
Current Alzheimer Research Cardiac Effect of Cholinesterase Inhibitors Used in Alzheimers Disease - from Basic Research to Bedside
Current Alzheimer Research Adipose Tissue: The Link Between Obesity and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Humanin; A Defender Against Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia
Current Medicinal Chemistry MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Prospective Role of MicroRNAs in Depression
Current Medicinal Chemistry Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Integration of Internet of Things with Quantum Dots: A State-of-the-art of Medicine
Current Pharmaceutical Design Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease
CNS & Neurological Disorders - Drug Targets